Kidney Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Kidney Cancer Therapeutics and Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The kidney cancer therapeutics and diagnostics market is expected to register a CAGR of nearly 6.46%, during the forecast period (2022-2027).

The COVID-19 pandemic affected healthcare systems and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. As per the JCO Global Oncology Journal article titled ‘Dual Challenge of Cancer and COVID-19: Impact on Health Care and Socioeconomic Systems in Asia Pacific’ published in June 2020 reported that for patients with cancer, there are significant negative implications when medical attention is diverted exclusively to the COVID-19 situation, overshadowing everyday clinical practice. These commonly include delays in diagnostic procedures and treatment. Additionally, the pandemic has also severely disrupted cancer screening, research, and clinical trials. Moreover, as per the report by International Kidney Cancer Coalition in July 2021, some advanced RCC patients were switched from intravenous to oral therapy or vice versa. Instead of combining therapies, opting for monotherapy due to the poor supply chain during COVID-19. The number of newly diagnosed patients has substantially fallen. Subsets of kidney cancer patients may be at a higher risk of poor outcomes. Some people with multiple sclerosis bilateral illness or lesion may have had a kidney transplant, and transplant patients have a significant COVID-19-related mortality rate. Thus, during the COVID-19 pandemic, the kidney cancer therapeutic and diagnostics market had severely impacted.

The market is primarily driven by the increase in the prevalence of kidney cancer and increased research and development expenditure from pharmaceutical companies. According to the report by International Kidney Cancer Coalition in July 2021, each year, around 431,000 people worldwide are diagnosed with kidney cancer. Additionally, according to the American Cancer Society 2022, around 431,288 persons will be diagnosed with kidney cancer worldwide in 2020. Thus, with the growing prevalence of kidney cancer, it is expected that the demand for kidney cancer therapeutics and diagnostics is an increase over the forecast period.

Additionally, product launches by the key market players support the market expansion over the forecast period. For instance, in February 2021, Glenmark Pharma released SUTIB, a generic kidney cancer treatment, in India. Sunitinib, an oral multikinase inhibitor (MKI), is effective in treating individuals with gastrointestinal stromal tumors and advanced renal cell carcinoma. Similarly, in September 2021, MSN Labs released Cabolong, a branded generic of Cabozantinib, for the treatment of renal cell carcinoma.

Thus, all the above-mentioned factors are expected to boost market growth over the forecast period. However, the high cost associated with the treatment and low success rate in clinical trials for cancer drugs may restrain the market growth over the forecast period.

Key Market TrendsClear cell RCC is Expected to be the Largest Growing Segment in the Kidney Cancer Therapeutics & Diagnostics Market

Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles. As per the National Cancer Institute in March 2020, reported that in adults, ccRCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. ccRCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases. Patients with ccRCC may have pain or feel tired. Sometimes, patients do not have any noticeable symptoms. Symptoms can include blood in the urine, pain, weight loss, feeling tired, fever, and a lump on the side.

According to the study published in the Karger Journal in April 2022, titled "The Early Diagnostic and Prognostic Value of BIRC5 in Clear-Cell Renal Cell Carcinoma Based on the Cancer Genome Atlas Data" high BIRC5 expression is a key indicator of ccRCC prognosis, making BIRC5 an excellent biomarker for predicting patient prognosis in ccRCC. BIRC5 may be a promising biomarker for the early detection of ccRCC. Thus, the adoption of various techniques in the diagnosis of ccRCC cancer is expected to boost the market as availability of the such techniques may help in the early diagnosis of ccRCC cancer.

In addition, growing research and development activity to identify the potential treatment option for ccRCC cancer is expected to boost segment growth. For instance, in August 2021, a study from the University of Pennsylvania's Perelman School of Medicine, the researchers discovered that the health of these specific cancer cells and tumors is dependent on cholesterol and this receptor, while also demonstrating that medication that precisely targets the receptor could make the cancer cells unable to survive and propagate. The study also reveals that lowering cholesterol through the diet may help to slow the formation of ccRCC tumors. According to the researchers, future trials will look into specific medicines and diets that can be utilized clinically to treat ccRCC. Thus, all aforementioned factors are expected to boost segment growth over the forecast period.

North America is found to be Leading the Kidney Cancer Therapeutics & Diagnostics Market

North America dominates the global kidney cancer therapeutics and diagnostics market. The major factor driving the growth is the increasing number of kidney cancer cases and product launches by the key market players. Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of an aging population, are expected to lead to the growth of the market in the forecast period.

According to the updates in 2022 by the American Cancer Society, in 2022, approximately 79,000 new cases of kidney cancer has diagnosed in the United States. Additionally, according to the Study titled "Clear Cell Renal Carcinoma" published in the National Library of Medicine in May 2022, every year, around 64,000 cases are reported in the United States. The incidence is highest between the ages of 60 and 80. Overall, the Black population has a worse outlook. Thus, the growing prevalence of kidney cancer in the United States is expected to increase the demand for diagnosis and treatment, thereby boosting the market growth.

Furthermore, growing product launches by the key market players are anticipated to boost market growth. For instance, in November 2021, Merck received Food and Drug Administration approval for Pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence following nephrectomy or nephrectomy and resection of metastatic lesions. Thus, all the above-mentioned factors are expected to boost the market in the North American region over the projected period.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market. Some of the key players are Abbott Laboratories, Amgen Inc., Bayer AG, Bristol- Mayers Squibb, F. Hoffmann-La Roche, Merck & Co. Inc, and among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.